VOOPOO
4.7.2022 09:17:05 CEST | Business Wire | Press release
VOOPOO’s 2022 "More Than Infinity " virtual product launch was held on June 29, 2022, where VOOPOO took 30 minutes to review its brand story during the past 8 years since its founding, expounding the connection between the “infinity symbol” and the brand spirit and demonstrating its commitment to creating infinite new possibilities using technology in 3 chapters. Meanwhile, the event was highlighted by 3 POD products featuring VOOPOO’s most cutting-edge technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220629005586/en/
A very important theme at the virtual event was telling the growth story of VOOPOO since its founding 8 years ago. Evolving from an atomization chip solution provider to today’s industry leader of open electronic atomization, VOOPOO has driven the positive development of the industry through a series of disruptive innovations while undergoing its own brand metamorphosis. In addition, since VOOPOO started the globalization strategy last year, it has opened branches in the United States, the United Kingdom, Indonesia, Germany, France, Canada, and Malaysia, and will open more in the future to strengthen localized operation in the local market. VOOPOO has also insisted on strengthening its global influence in the global electronic atomization field by setting up brand flagship stores and launching APPs in more regions.
As another essential part of the event, VOOPOO released the three latest Pod products, of which two V-series products, namely VMATE E and VMATE Infinity Edition, were unveiled for the first time. Both products are equipped with the newly upgraded cartomizer, using the 5A freshness seal technology to lock the fresh taste and aroma of the e-liquid, while the Fresnel lens texture design can effectively reduce the e-liquid’s exposure to light, preserving the fresh taste for users. The material of the cartridge is specially added with silver ions with 99%+ effective antibacterial performance.
The third product Drag Q which was previously released came back with a new CMF Infinity Edition. As a POD product, Drag Q has subverted the industry's understanding of POD products with its expert-level performance in intelligent pressure control and taste restoration. At the virtual launch, the VOOPOO global brand ambassador also explained in detail the core drive of VOOPOO’s leapfrog development, i.e., the investment in “user-centered” R&D. So far, VOOPOO has launched three pioneering atomization platforms catering to different users -- PNP, TPP, ITO , and has developed two GENE chips for different product functions -- GENE AI and GENE TT . It is with the continuous optimization and innovation in atomization technology that VOOPOO wins trust and support of consumers.
Infinite connections: join hands with 100,000+ customers and 50,000,000+ fans to build an electronic atomization culture
The last chapter was dedicated to the customers and millions of fans who marched forward hand in hand with VOOPOO. In the past 8 years, VOOPOO has cooperated closely with more than 100,000 offline outlets, and has won more and more consumers with high-quality products and continuous market investment. Its market achievements are the evidence of mutual benefit and win-win cooperation with partners. On a global scale, more than 50 million users have become loyal fans of VOOPOO. They not only spur VOOPOO to continue to create products that are ahead of the times but also become part of the electronic atomization culture in the VOOPOO ecosystem. VOOPOO announced that the first flagship stores, being part of the VOOPOO ecosystem, will open in the UK and Indonesia for close interaction with VOOPOO fans.
VOOPOO took 30 minutes to demonstrate the connection between VOOPOO’s development strategy, innovative spirit, brand culture and the infinity symbol, while the 3 newly launched products will be worthy of the expectations of the market and the industry.
About VOOPOO
VOOPOO is a leading brand of open pod system and has rapidly risen through DRAG products, which have been widely acclaimed globally in a short period of time. VOOPOO focuses on building two core technology platforms of [Chip] and [Atomization]. VOOPOO has creatively developed GENE.AI, GENE.TT and other chips. In addition, VOOPOO independently developed three Atomization Platforms, which are TPP,PNP,ITO, aiming at differentiated users. VOOPOO has four major product series - ARGUS, DRAG, VINCI, and V-series(Doric). VOOPOO will continue to develop more national markets in the future, aiming to build one of the most influential global brands.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220629005586/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
Sutherland Launches FinAI Hub to Industrialize Agentic AI for Banking and Financial Services6.3.2026 14:00:00 CET | Press release
A domain-trained AI agent workforce enables production-scale AI across regulated financial institution operations Today, Sutherland announced the launch of Sutherland FinAI Hub, an enterprise Agentic AI platform built exclusively for Banking and Financial Services. As financial institutions accelerate AI adoption, many initiatives remain confined to pilots, unable to scale across legacy systems and core operations. Sutherland FinAI Hub is designed to help close that gap. FinAI Hub is an innovation ecosystem where Sutherland works with clients to design, prototype, and scale Agentic AI workflows across core operations. At launch, the platform brings together a large and expanding workforce of domain-trained AI agents purpose-built for financial institutions, supporting functions across retail banking, payments, cards, consumer and commercial lending, servicing, back office, risk and compliance functions. These modular agents can operate independently or be orchestrated across end-to-end
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
